We are pleased to announce that Unison Capital Partners, IV, LPS and Unison Capital Partners IV (F), L.P. have entered into an agreement with a special purpose company jointly funded by Oji Holdings Corporation (“Oji HD”) and Unison Capital Partners, VI, LPS to transfer the shares of LTL Pharma Co., Ltd. (“LTL Pharma”), and have completed the closing today.

LTL Pharma was established by Unison as a dedicated platform for long-listed pharmaceutical products. Its mission is to meet two critically important and socially valuable needs of the pharmaceutical industry: supporting new drug development and ensuring the long-term stable supply of long-listed products.

Oji Pharma Co., Ltd., a wholly owned subsidiary of Oji HD, is engaged in research and development of animal health and pharmaceutical products derived from natural capital.

Together with Oji HD, Unison will continue to actively engage in discussions with pharmaceutical companies regarding product succession and aim to expand the range of products handled by LTL Pharma.